

Applicants : Aharoni, et al.  
Serial No. : 09/768,872  
Filed : January 23, 2001  
Page 2

In the Claims

Please amend the claims by replacing all prior versions, and listings, of claims pursuant to 37 C.F.R. §1.121(c) as follows:

1-15. (canceled)

16. (Currently amended) A pharmaceutical composition comprising an amount of a mixture of terpolymers effective to treat an autoimmune disease, and a pharmaceutically acceptable carrier, wherein each terpolymer consists essentially of randomly polymerized tyrosine, alanine and lysine.

17-18. (canceled)

19. (Previously presented) The pharmaceutical composition of Claim 16, wherein said tyrosine is present in a mole fraction of about 0.005 to about 0.250; said alanine is present in a mole fraction of about 0.3 to about 0.6; and lysine is present in a mole fraction of about 0.1 to about 0.5.

20. (Previously presented) The pharmaceutical composition of Claim 16, wherein said tyrosine is present in a mole fraction of 0.10, said alanine is present in a mole fraction of 0.54, and said lysine is present in a mole fraction of 0.35.

21-31. (canceled)

32. (Previously presented) The pharmaceutical composition of Claim 16 wherein said mixture of terpolymers has an

Applicants : Aharoni, et al.  
Serial No. : 09/768,872  
Filed : January 23, 2001  
Page 3

average molecular weight of about 2,000 to about 40,000 daltons.

33. (Previously presented) The pharmaceutical composition of Claim 16 wherein said mixture of terpolymers has an average molecular weight of about 4,000 to about 9,000 daltons.
34. (original) The pharmaceutical composition of Claim 16, wherein said autoimmune disease is a B cell mediated autoimmune disease.
35. (original) The pharmaceutical composition of Claim 16, wherein said autoimmune disease is a T cell mediated autoimmune disease.
36. (original) The pharmaceutical composition of Claim 16, wherein said autoimmune disease is an arthritic condition.
37. (original) The pharmaceutical composition of Claim 16, wherein said autoimmune disease is a demyelinating disease.
38. (original) The pharmaceutical composition of Claim 16, wherein said autoimmune disease is an inflammatory disease.
39. (original) The pharmaceutical composition of Claim 16, wherein said autoimmune disease is multiple sclerosis, autoimmune hemolytic anemia, autoimmune oophoritis, autoimmune thyroiditis, autoimmune uveoretinitis, chronic immune thrombocytopenic purpura, colitis, contact

Applicants : Aharoni, et al.  
Serial No. : 09/768,872  
Filed : January 23, 2001  
Page 4

sensitivity disease, diabetes mellitus, Graves disease, Guillain-Barre's syndrome, Hashimoto's disease, idiopathic myxedema, myasthenia gravis, psoriasis, pemphigus vulgaris, rheumatoid arthritis, or systemic lupus erythematosus.

40-156. (canceled)

157. (Currently amended) A method for treating a subject afflicted with an autoimmune disease which comprises administering to the subject ~~an amount of a terpolymer effective to treat the autoimmune disease, wherein the terpolymer consists essentially of randomly polymerized tyrosine, alanine and lysine~~ the pharmaceutical composition of claim 16.

158. (Previously presented) The method of claim 157, wherein the autoimmune disease is multiple sclerosis, autoimmune hemolytic anemia, autoimmune oophoritis, autoimmune thyroiditis, autoimmune uveoretinitis, chronic immune thrombocytopenic purpura, colitis, contact sensitivity disease, diabetes mellitus, Graves disease, Guillain-Barre's syndrome, Hashimoto's disease, idiopathic myxedema, myasthenia gravis, psoriasis, pemphigus vulgaris, rheumatoid arthritis, or systemic lupus erythematosus.

159. (Previously presented) The method of claim 158, wherein the autoimmune disease is multiple sclerosis.

160. (Previously presented) The method of claim 158, wherein the autoimmune disease is rheumatoid arthritis.

Applicants : Aharoni, et al.  
Serial No. : 09/768,872  
Filed : January 23, 2001  
Page 5

161. (Previously presented) The method of claim 160, wherein the amount of the terpolymer is at least 5 mg/day.
162. (Previously presented) The method of claim 161, wherein the amount of the terpolymer is at least 10 mg/day.
163. (Previously presented) The method of claim 162, wherein the amount of the terpolymer is at least 15 mg/day.
164. (Previously presented) The method of claim 163, wherein the amount of the terpolymer is at least 20 mg/day.
165. (Previously presented) The method of claim 160, wherein the amount of the terpolymer is 25-400 µg/kg of the subject per day.